Bray, F. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21492 (2018).
Zardavas, D., Irrthum, A., Swanton, C. & Piccart, M. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 12, 381–394 (2015).
Peto, R. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432–444 (2012).
Florea, A. M. & Busselberg, D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, (1351–1371 (2011).
Colombo, P. E., Milanezi, F., Weigelt, B. & Reis-Filho, J. S. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 13, 212 (2011).
Borst, P. & Wessels, L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 9, 4836–4840 (2010).
Jung, Y. et al. SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy. Cancer Res. 73, 6951–6962 (2013).
Li, L. et al. SHON, a novel secreted protein, regulates epithelial-mesenchymal transition through transforming growth factor-beta signaling in human breast cancer cells. Int J. Cancer 136, 1285–1295 (2015).
Abd El-Rehim, D. M. et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J. Cancer 116, 340–350 (2005).
Abdel-Fatah, T. M. et al. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 17, 1004–1018 (2016).
Green, A. R. et al. Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. J. Pathol. Clin. Res 2, 32–40 (2016).
McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97, 1180–1184 (2005).
Hammond, M. E., Hayes, D. F., Wolff, A. C., Mangu, P. B. & Temin, S. American society of clinical oncology/college of american pathologists’ guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 6, 195–197 (2010).
Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118–145 (2007).
Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med 351, 2817–2826 (2004).
Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006).
Planque, N. Nuclear trafficking of secreted factors and cell-surface receptors: new pathways to regulate cell proliferation and differentiation, and involvement in cancers. Cell Commun. Signal 4, 7 (2006).
Bryant, D. M. & Stow, J. L. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic 6, 947–954 (2005).
Zhen, Y. et al. Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnalpha1 and Kpnbeta1. Traffic 13, 650–664 (2012).
Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616–630 (2012).
Chen, W. & Ten, D. P. Immunoregulation by members of the TGFbeta superfamily. Nat. Rev. Immunol. 16, 723–740 (2016).
Wu, L. et al. Smad4 as a transcription corepressor for estrogen receptor alpha. J. Biol. Chem. 278, 15192–15200 (2003).
Xiong, Z. et al. Synergistic repression of estrogen receptor transcriptional activity by FHL2 and Smad4 in breast cancer cells. IUBMB Life. 62, 669–676 (2010).
Duffy, M. J. et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer 75, 284–298 (2017).
Colomer, R. et al. Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin. Transl. Oncol. 20, 815–826 (2018).
Vieira, A. F. & Schmitt, F. An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Front Med. 5, 248 (2018).
Krop, I. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 35, 2838–2847 (2017).
Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast Cancer. N. Engl. J. Med. 379, 111–121 (2018).
Hayes, D. F., Khoury, M. J. & Ransohoff, D. Why hasn't genomic testing changed the landscape in clinical oncology? Am Soc Clin Oncol Educ. Book e52–e55 (2012). https://doi.org/10.14694/EdBook_AM.2012.32.e52.
Sgroi, D. C. The HOXB13:IL17BR gene-expression ratio: a biomarker providing information above and beyond tumor grade. Biomark. Med. 3, 99–102 (2009).
Bosl, A. et al. MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer. PLoS ONE 12, e0183458 (2017).
Nunes, R. A. et al. Genomic profiling of breast cancer in African-American women using MammaPrint. Breast Cancer Res Treat. 159, 481–488 (2016).
Kok, M. & Linn, S. C. Gene expression profiles of the oestrogen receptor in breast cancer. Neth. J. Med. 68, 291–302 (2010).
Finetti, P. et al. ESPL1 is a candidate oncogene of luminal B breast cancers. Breast Cancer Res Treat. 147, 51–59 (2014).
Rimm, D. L. et al. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod. Pathol. 32, 59–69 (2019).
Bertucci, F., Viens, P. & Birnbaum, D. SPAG5: the ultimate marker of proliferation in early breast cancer? Lancet Oncol. 17, 863–865 (2016).
Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275–1281 (2008).
von, M. G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
McAndrew, N. & DeMichele, A. Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer. J. Target Ther. Cancer 7, 52–69 (2018).
Montemurro, F. & Aglietta, M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr. Relat. Cancer 16, 1091–1102 (2009).
Joerger, M. & Thurlimann, B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev. Anticancer Ther. 13, 165–178 (2013).
Sansregret, L., Vanhaesebroeck, B. & Swanton, C. Determinants and clinical implications of chromosomal instability in cancer. Nat. Rev. Clin. Oncol. 15, 139–150 (2018).
Munro, A. F., Twelves, C., Thomas, J. S., Cameron, D. A. & Bartlett, J. M. Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. Br. J. Cancer 107, 71–74 (2012).
Jamal-Hanjani, M. et al. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Ann. Oncol. 26, 1340–1346 (2015).
McGranahan, N., Burrell, R. A., Endesfelder, D., Novelli, M. R. & Swanton, C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 13, 528–538 (2012).